Divi's Lab Stock Key News

Key News Driving the Stock Strong Q4 FY25 Results: The company announced strong Q4 results, with a significant jump in net profit (around 23-26% year-on-year) and revenue growth (around 12% year-on-year). Consolidated net profit stood at ₹662 crore compared to ₹538 crore in the same quarter last year. Revenue from operations grew to ₹2,585 crore from ₹2,303 crore year-on-year. Dividend Recommendation: The board has recommended a final dividend of ₹30 per equity share for the financial year 2024-25. The record date for the dividend is July 25, 2025. Commencement of Unit III Operations: The company's Unit III greenfield project at Ontimamidi Village commenced commercial operations during the reported quarter. A significant portion of the capital expenditure for the year was related to this unit. Appointment of New CFO: The board approved the appointment of Venkatesa Perumallu Pasumarthy as the new Chief Financial Officer, effective August 1, 2025, following the superannuation of the current CFO. Future Plans and Outlook: Capacity Expansion: The commencement of Unit III is a key part of the company's expansion plans. Backward Integration: Phase I of the Kakinada facility (Unit III) will focus on backward integration and manufacturing starting materials. Generics Growth: The company anticipates growth in the generics segment, potentially driven by patent expirations. Custom Synthesis: There is a focus on growing the custom synthesis business, with increased RFPs and customer visits. New Facility Investment: Divi's Laboratories previously announced an investment of around ₹1,500 crore for setting up the Unit-III facility.